Avrobio Inc (AVRO)

$1.51

+0.1

(+7.09%)

Market is closed - opens 7 PM, 28 May 2024

Insights on Avrobio Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 67.0% return, outperforming this stock by 39.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 238.7% return, outperforming this stock by 319.9%

Performance

  • $1.45
    $1.51
    $1.51
    downward going graph

    3.97%

    Downside

    Day's Volatility :3.97%

    Upside

    0.0%

    downward going graph
  • $0.88
    $1.65
    $1.51
    downward going graph

    41.72%

    Downside

    52 Weeks Volatility :46.66%

    Upside

    8.48%

    downward going graph

Returns

PeriodAvrobio IncSector (Health Care)Index (Russel 2000)
3 Months
16.15%
-1.8%
0.0%
6 Months
20.8%
10.1%
0.0%
1 Year
27.97%
13.2%
0.0%
3 Years
-81.24%
17.0%
-21.4%

Highlights

Market Capitalization
63.3M
Book Value
$2.12
Earnings Per Share (EPS)
0.27
PE Ratio
5.22
Wall Street Target Price
2.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-40.62%
Return On Equity TTM
14.29%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-66.0M
Diluted Eps TTM
0.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.48
EPS Estimate Next Year
-0.17
EPS Estimate Current Quarter
-0.36
EPS Estimate Next Quarter
-0.08

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Avrobio Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
10
Hold
1
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 32.45%

Current $1.51
Target $2.00

Technicals Summary

Sell

Neutral

Buy

Avrobio Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Avrobio Inc
Avrobio Inc
24.79%
20.8%
27.97%
-81.24%
-90.31%
Moderna, Inc.
Moderna, Inc.
54.31%
114.37%
31.98%
-5.11%
673.49%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
11.53%
23.42%
35.86%
98.13%
219.88%
Novo Nordisk A/s
Novo Nordisk A/s
7.24%
30.97%
66.95%
238.66%
467.54%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
14.96%
30.49%
38.47%
120.96%
164.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Avrobio Inc
Avrobio Inc
5.22
5.22
NA
-0.48
0.14
-0.41
NA
2.12
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.6
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.99
28.99
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.75
46.75
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.23
29.23
0.53
17.14
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Avrobio Inc
Avrobio Inc
Buy
$63.3M
-90.31%
5.22
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$63.9B
673.49%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
219.88%
28.99
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$605.7B
467.54%
46.75
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.3B
164.5%
29.23
39.46%

Institutional Holdings

  • BML Capital Management LLC

    8.91%
  • Vanguard Group Inc

    4.19%
  • Acadian Asset Management LLC

    2.76%
  • Newtyn Management LLC

    2.49%
  • Aisling Capital Management LP

    2.25%
  • Renaissance Technologies Corp

    1.69%

Company Information

clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.

Organization
Avrobio Inc
Employees
13
CEO
Mr. Erik John Ostrowski M.B.A.
Industry
Health Technology

FAQs